Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $39M (down 56.4% year over year) with net income of −$81M.
Q3 2025 key financials · XBRL
- Revenue
- $39M
- −56.4% YoY · −21.7% QoQ
- Net income
- −$81M
- −43.2% YoY · −33.9% QoQ
- Operating margin
- -231.8%
- EPS (diluted)
- −$1.45
- +82.7% YoY · −33.0% QoQ
Source: XBRL data from the Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 10-Q on SEC EDGAR. USD.
Ginkgo Bioworks Holdings, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $38.8M, down $50.2M YoY from $89.0M
- Cell Engineering $29.4M, down $45.7M; Biosecurity $9.5M, down $4.5M
- Operating loss $90.0M versus $55.2M YoY; net loss $80.8M versus $56.4M
- R&D expense $69.4M, down $7.7M; G&A expense $45.0M, down $7.3M
- 2025 R&D and G&A expenses expected consistent or declining versus 2024; restructuring actions substantially completed in 2025
Risk Factors
- No risk-factors section provided in the submitted text
- No newly added risk identified from the provided filing excerpt
- No regulatory, legal, operational, competitive, market, or financial risk details available in the excerpt
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Ginkgo Bioworks Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.